

10/501223

PATENT

0508-1107

DTG Rec'd PCT/PTO 12 JUL 2004

IN THE U.S. PATENT AND TRADEMARK OFFICE

#3

In re application of

Christophe GUILLON et al.

Conf.

Application No. **NEW NATIONAL PHASE**

Group

Filed July 12, 2004

Examiner

HIV-1 VIRUS TAT-PROTEIN MUTANTS

INFORMATION DISCLOSURE STATEMENT
(SUBMISSION CONCURRENT WITH THE
FILING OF A NEW PATENT APPLICATION)

Assistant Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

July 12, 2004

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, and in fulfillment of the duty of disclosure under 37 C.F.R. § 1.56, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications, or other information submitted for consideration by the Office are listed on PTO-1449, attached hereto.

II. COPIES

- ☐ Copies of the U.S. patents or publications are not submitted since the USPTO has waived their submission for applications filed after June 30, 2003.
- ☐ Submitted herewith is a legible copy of (i) each foreign patent; (ii) each publication or that portion which caused it to be listed; and (iii) all other information or that portion which caused it to be listed.
- ☒ This application is a National Phase of a PCT application. Some or all of the documents listed on the PTO-1449 are not enclosed because they were cited in the International Search Report and copies should have been forwarded from the International Search Authority pursuant to the trilateral agreement between the USPTO, EPO and JPO, or they are U.S. patents or U.S. published applications. If copies are needed, please contact the undersigned.

III. CONCISE EXPLANATION OF THE RELEVANCE
(check at least one box)

DT04 PCT/PTO 12 JUL 2004

a. ☐ **DOCUMENTS IN THE ENGLISH LANGUAGE**

The attached non U.S. patents, non U.S. patent application publications, foreign publications, or other information in the English language do not require a statement of relevancy.

b. ☐ **DOCUMENTS NOT IN THE ENGLISH LANGUAGE**

A concise explanation of the relevance of all patents, publications, or other information listed that is not in the English language is as follows:

c. ☒ **FOREIGN SEARCH REPORT OR ACTION**

An foreign language version of the search report or action that indicates the degree of relevance found by the foreign office is attached, thereby satisfying the requirement for a concise explanation. See MPEP 609(A)(3).

d. ☐ **OTHER**

The following additional information is provided for the Examiner's consideration.

FEES

This Information Disclosure Statement is being filed concurrently with the filing of a new patent application; therefore, no fee is required.

If The Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned.

Respectfully submitted,

YOUNG & THOMPSON



Benoit Castel, Reg. No. 35,041
745 South 23rd Street
Arlington, VA 22202
Telephone (703) 521-2297
Telefax (703) 685-0573
703) 979-4709

BC/maf

Enclosures: ☒ Form PTO-1449(s)
☒ Documents
☒ Foreign Search Report
☐ Other: _____

**INFORMATION DISCLOSURE CITATION
IN AN APPLICATION**

(Use several sheets if necessary)

Attorney Docket No.:

0508-1107

Application No.:

NEW NATIONAL PHASE

Applicant:

Christophe GUILLON et al.

Filing Date:

July 12, 2004

Group Art Unit:

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing date (if appropriate)

FOREIGN PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
	96/28189	9/19/1996	PCT				
	2 792 204	10/20/2000	FRANCE				
	99/27958	6/10/1999	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Orsini. "Inhibition of Human Immunodeficiency Virus Type 1 and Type 2 Tat function by transdominant Tat protein localized to both the nucleus and cytoplasm," J. Virol., vol. 70, no. 11, November 1996 (1996-11), pages 8055-8063, XP002214873
	Goldstein, "HIV - Tat protein as a potential AIDS vaccine," Nature Medicine, Nature Publishing, Co., US, vol. 2, no. 9, September 1996 (1996-09), pages 960-964, XP002129594 ISSN: 1078-8956.
	Le Buanec et al., "A prophylactic and therapeutic AIDS vaccine containing as a component the innocuous Tat Toxoid," Biomed & Pharm. 1998, vol. 52, pages 431-435, XP000867754.
	Brake et al., "Characterization of Murine Monoclonal Antibodies to the Tat Protein from Human Immunodeficiency Virus Type 1," Journal of Virology, The American Society for Microbiology, US, Vol. 64, Feb 1990 (1990-02), p. 962-965, XP002912805, ISSN: 0022-538X
	Caselli et al., "DNA Immunization with HIV-1 <i>tat</i> Mutated in the <i>trans</i> Activation Domain Induces Humoral and Cellular Immune Responses Against Wild-Type Tat", The Journal of Immunology, The Williams and Wilkins Co. Baltimore, US, vol. 162, no. 9, May 1, 1999 (1999-05-01), pages 5631-5638, XP002129597, ISSN: 0022-1767

EXAMINER:

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

* English language abstract provided for the Examiner's convenience

Best Available Copy

Y&T July 12, 2004